CLINICAL_TRIALS ClinicalTrials.gov record update

Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03208322
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:38.352040+00:00
Published At: 2022-05-27T00:00:00+00:00
Record Updated At: 2022-05-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hepatitis C"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-05-27"
protocolSection.identificationModule.nctId: "NCT03208322"
protocolSection.identificationModule.officialTitle: "Early Post-marketing Study of Daclatasvir (Daklinza\u00ae) + Asunaprevir (Sunvepra\u00ae) in the Treatment of Chronic Hepatitis C (CHC) in Adults"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.